Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS)
NCT07364045 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104
Last updated 2026-03-04
Summary
This study aims to investigate how fat accumulation in the pancreas contributes to the development of type 2 diabetes (T2D), and how weight loss may reverse this process. Previous research has shown that reducing body weight can lead to diabetes remission, and this was accompanied by lowering intrapancreatic fat and restoration of insulin secretion, but the mechanisms behind this are not fully understood. In particular, the study aims to unravel the role of hepatic de novo lipogenesis (DNL) and lipoprotein metabolism on pancreas lipotoxicity and beta cell recovery after weight loss.
Four groups of participants will be recruited (n=26 per group): non-diabetic, pre-diabetic, short-duration T2D (\<6 years), and long-duration T2D (\>10 years). Participants will be aged between 45 and 79 years and have a BMI between 30 and 45 kg/m². All participants will follow a structured weight loss programme using an 800 kcal/day Total Diet Replacement (TDR) for 8-12 weeks, followed by dietary support to maintain weight loss. The study is sponsored by NHS-Lothian and the University of Edinburgh and will be carried out at the Clinical Research Facility, Royal infirmary of Edinburgh by a specialist team (Senior Diabetes Research Nurse, Clinical Fellow, and Research Dietitian).
The primary endpoint of this study is to achieve a 10-15% reduction in body weight (\~10 kg) through a low-calorie diet (800 kcal/day) to induce T2D remission and maintain this weight loss with structured dietary support for up to 6-12 months. The primary aim is to compare hepatic de novo lipogenesis-the conversion of sugar into fat by the liver-and lipoprotein export among the groups, and to examine how these parameters change in response to weight loss, improvement in metabolic status, and restoration of normal pancreatic function.
Secondary endpoints include changes in weight, HbA1c, intraorgan fat (liver/pancreas), pancreas volume and tissue characteristics, beta cell mass and function (MRI/mixed meal test), circulating blood markers (i.e. lipids, exosomes, adipokines, and inflammatory markers), and the change in adipose tissue biology (fat biopsies).
Ultimately, this study aims to understand the mechanisms of T2D remission. It will help clarify the sequence of metabolic events leading to reversible pancreatic lipotoxicity and may inform the development of new, targeted therapies for T2D.
Conditions
Interventions
- BEHAVIORAL
-
Total Diet Replacement (TDR) Program
Participants will follow a structured Total Diet Replacement (TDR) program consisting of approximately 800 kcal/day using commercially available soups and shakes for 8-12 weeks. This is followed by a 2-week food reintroduction phase and a weight maintenance phase up to 6 months, supervised by a research dietitian. The intervention aims to induce rapid weight loss and assess its impact on intrapancreatic fat, insulin secretion, and type 2 diabetes remission. All participants receive dietary counseling and monitoring throughout the study.
Sponsors & Collaborators
-
NHS Lothian
collaborator OTHER_GOV -
University of Edinburgh
lead OTHER
Principal Investigators
-
Ahmad Al-Mrabeh, PhD · University of Edinburgh
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 45 Years
- Max Age
- 79 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-30
- Primary Completion
- 2029-03-30
- Completion
- 2029-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans
NCT01953393 ·Status: COMPLETED ·Phase: NA
-
Regulation of Tissue Lipolysis by Insulin in Type 2 Diabetes
NCT01680133 ·Status: COMPLETED
-
A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)
NCT07355270 ·Status: RECRUITING ·Phase: NA
-
Avoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics
NCT06782568 ·Status: RECRUITING ·Phase: NA
-
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
NCT05597202 ·Status: UNKNOWN ·Phase: PHASE4
-
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
NCT02833415 ·Status: COMPLETED ·Phase: PHASE4
-
Dietary Strategies for Remission of Type 2 Diabetes
NCT04943926 ·Status: RECRUITING ·Phase: NA
-
Combined Active Treatment in Type 2 Diabetes with NASH
NCT04639414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes
NCT02344186 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
NCT02637973 ·Status: COMPLETED ·Phase: PHASE4
-
Pancreatic Calcium Handling in Islet Beta Cells in Patients With Type 1 Diabetes Mellitus
NCT05298735 ·Status: COMPLETED
-
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
NCT02592421 ·Status: COMPLETED ·Phase: PHASE3
-
Glucagon Resistance in Patients With MASLD and T2DM
NCT07246421 ·Status: RECRUITING ·Phase: NA
-
Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy
NCT02175459 ·Status: RECRUITING
-
Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients
NCT01374594 ·Status: COMPLETED
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
NCT05093517 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
NCT00795600 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
NCT07012642 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes
NCT02413567 ·Status: COMPLETED ·Phase: NA
-
Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia
NCT02337660 ·Status: COMPLETED ·Phase: NA
-
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
NCT03582956 ·Status: TERMINATED ·Phase: NA
-
Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota
NCT04151849 ·Status: COMPLETED
-
Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects
NCT03682172 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Low Dose Fat-Induced Insulin Resistance
NCT03479671 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2
NCT02009410 ·Status: WITHDRAWN ·Phase: PHASE4